RxDoctor Payments Data

Robert Thomson, MD

Internal Medicine · Rochester, NYNPI 1144267329

Payments from drug & device makers

$9,364in general payments, 2019–2025

Across 603 payments — averaging $15.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$864
  • AstraZeneca$785
  • Pfizer$741
  • Lilly USA, LLC$615
  • GSK$601
  • plus $4K from 44 others

What the payments were for

  • Food & beverage$9,05197%
  • Education$1061%
  • Other$2082%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,364 in reported general payments places this provider in the 90th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$77,294
Medicare patients
165
Services billed
1,030

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban138$153,477
OzempicSemaglutide95$108,269
JardianceEmpagliflozin66$93,110
FarxigaDapagliflozin Propanediol56$65,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter66$64,125
LinzessLinaclotide37$31,018
ProliaDenosumab17$27,867
MounjaroTirzepatide24$26,022
RybelsusSemaglutide11$20,092
TrulicityDulaglutide13$18,152
Nurtec OdtRimegepant Sulfate14$17,875
AbrysvoRsv Vacc, Pref A And Pref B/Pf44$13,967
Repatha SureclickEvolocumab13$13,747
Atorvastatin Calcium788$13,688
MyrbetriqMirabegron18$13,318

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt, Abrysvo$741$185,318196 claims
Novo NordiskOzempic, Rybelsus$864$128,361106 claims
Boehringer IngelheimJardiance, Spiriva Respimat$447$98,93177 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$601$85,271122 claims
AstraZenecaFarxiga, Breztri Aerosphere$785$73,83467 claims
Lilly USA, LLCMounjaro, Trulicity$615$44,17437 claims
AbbVieLinzess, Restasis$1,496$39,03949 claims
AmgenProlia$475$27,86717 claims
Astellas Pharma US IncMyrbetriq$292$13,31818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →